HYTN Innovations Inc. announced that it has been granted a Drug Establishment License (DEL) by Health Canada. This license allows HYTN to engage in the GMP fabrication, packaging, and labeling of non-sterile pharmaceuticals containing both cannabis and psilocybin, significantly enhancing the Company's capabilities and expanding its market reach. With this license, HYTN is now positioned to manufacture and export these pharmaceutical products into regulated global markets, further solidifying its status as one of the very few companies in the sector with these capabilities.

The award of the DEL is a testament to HYTN's expertise and sophistication in GMP drug manufacturing, a requirement for many international markets including the UK, Germany and Australia. This accomplishment builds on the Company's existing GMP certification under the International Pharmaceutical Inspection Scheme "PIC/S", issued by the Australian Therapeutic Goods Administration (TGA). The new license not only expands HYTN's operational scope but also underscores its commitment to maintaining the highest standards of quality and compliance in the pharmaceutical industry.

With the DEL now in hand, HYTN plans to accelerate its production and distribution of non-sterile pharmaceutical's. The Company is strategically positioned to capitalize on the growing demand for these products in regulated markets worldwide. In accordance with the Company's approved omnibus plan and in recognition of this achievement, the company's officers and operators have been granted awards commensurable to their individual agreements totaling 3,080,000 Restricted Share Units.